On Wednesday, for the first time since Pfizer's takeover of Wyeth, which happened in October of last year and cost the giant pharmaceutical company a whopping $68 Billion, the company provided an update of its pipeline of experimental drugs.

The pipeline, which is composed of assets from both the large-scale companies, includes about 133 programs across 6 major research areas - oncology, pain, inflammation, Alzheimer’s disease, psychoses and diabetes.

“This pipeline of investigational medicines represents the strong future of Pfizer. Since the closing of the Wyeth transaction late last year, we have made strategic decisions about our R&D resources, global footprint and high-priority projects. Our focus now turns to delivery of these health solutions for patients around the world", said Martin Mackay, President of Pfizer’s Pharmatherapeutics Research and Development Division.

As has been shared by the company, the 133 programs have a total of some 500 new medicine candidates, which are in various stages of clinical development. These experimental medicines were selected from among the 600 drugs that were already in the pipelines of both these firms at the time of takeover.